Todd Bazemore

Todd Bazemore is the President and CEO of AIRNA, a Cambridge, Massachusetts biotech developing RNA-editing medicines that rewrite disease-causing genetic variants without permanently altering DNA. Appointed in June 2026, he arrived as the company's lead program, AIR-001 for alpha-1 antitrypsin deficiency, moved into the clinic on the back of an oversubscribed $155 million Series B. A University of Massachusetts Lowell graduate with more than 30 years in rare-disease drug development, he previously ran Kala Bio, led U.S. operations at Santhera, and was chief commercial officer at Dyax during its $6.5 billion acquisition by Shire.